Latest Breaking News On - Mark lappe - Page 1 : comparemela.com

French pharma giant Sanofi buys San Diego biotech for $2.2B

The deal gives Sanofi access to Inhibrx's therapy for a genetic disorder that raises a patient's risk for lung cancer and other disease

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 billion

French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday. As part of this deal, Inhibrx shareholders will get $30 per share in cash, one contingent value right (CVR) equal to $5 and 0.25 shares in New Inhibrx, a new publicly traded company. Following the closing of the deal, New Inhibrx will continue to operate under the "Inhibrx" name and will be led by Mark Lappe as Chairman and CEO.

Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101.

Sanofi buys the American INBRX-101 project for around $2.2 billion